Alexion Pharmaceuticals, Inc. (ALXN) said it has submitted marketing applications to the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA, for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome, or aHUS.
The company specified that both the US and EU filings include the positive data from the two 26-week Phase 2 studies of Soliris as a treatment for adult and adolescent patients with aHUS.
Further, Alexion raised its fiscal-2011 revenue forecast to the range of $720 to $740 million from the previously announced range of $715 to $735 million. Analysts anticipated revenues of $735.54 million for the year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.